Neuraceq 5000 MBq Solution is a Health Canada–registered radiopharmaceutical drug (DIN 02461927) held by Isologic Innovative Radiopharmaceuticals Ltd., containing Florbetaben (18f). Health Canada lists its status as Marketed (status date 13 Aug 2018). Nexara Health has matched 6 registrations of Florbetaben (18f) across 6 other regulated markets.
Health Canada registration
| DIN | 02461927 |
|---|---|
| Brand name | Neuraceq |
| Active ingredient | Florbetaben (18f) |
| Strength | 5000 MBq |
| Dosage form | Solution |
| Route | Intravenous |
| Company | Isologic Innovative Radiopharmaceuticals Ltd. |
| Status | Marketed — 13 Aug 2018 |
| Class | Radiopharmaceutical |
| ATC | V09AX06 FLORBETABEN 18F |
| AHFS | |
| Regulator record | Health Canada DPD entry · Product monograph |
Florbetaben (18f) registered in other markets
6 registrations of the same molecule in 6 national registries outside Canada. Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Czech Republic | Neuraceq | — | 300MBQ/ML | Inj Sol | R | SUKL DLP |
| Denmark | Neuraceq | Life Molecular Imaging GmbH | 300 MBq/ml | injektionsvæske, opløsning | Central | Laegemiddelstyrelsen |
| European Union (EMA) | Neuraceq | Lantheus Germany GmbH | Authorised | EMA centrally authorised | ||
| Finland | Neuraceq | Lantheus Germany GmbH | 300 MBq/ml | injektioneste, liuos | Myyntilupa myönnetty | Fimea Perusrekisteri |
| Netherlands | Neuraceq 300 MBq/mL, oplossing voor injectie | Life Molecular Imaging GmbH | Oplossing voor injectie | Uitsluitend recept | EU national register | |
| Poland | Neuraceq | Life Molecular Imaging GmbH | 300 MBq/ml | Roztwór do wstrzykiwań | URPL RPL |
See every manufacturer of Florbetaben (18f) worldwide →
Related molecules (ATC V09AX)
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Neuraceq (DIN 02461927) marketed in Canada?
Yes. Health Canada lists DIN 02461927 as Marketed as of 13 Aug 2018.
Who holds the Canadian licence for this product?
Isologic Innovative Radiopharmaceuticals Ltd. is the company of record in the Health Canada Drug Product Database.
Is Florbetaben (18f) registered outside Canada?
Yes — Nexara Health has matched 6 registrations in 6 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02461927, status date 2018-08-13; national medicine registries: EMA centrally authorised, EU national register, Fimea Perusrekisteri, Laegemiddelstyrelsen, SUKL DLP, URPL RPL. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02461927, status date 2018-08-13; national medicine registries: EMA centrally authorised, EU national register, Fimea Perusrekisteri, Laegemiddelstyrelsen, SUKL DLP, URPL RPL.
Health Canada Drug Product Database (DPD), DIN 02461927, status date 2018-08-13; national medicine registries: EMA centrally authorised, EU national register, Fimea Perusrekisteri, Laegemiddelstyrelsen, SUKL DLP, URPL RPL. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.